Sirolimus human studies: what the trials actually show

Last updated 2026-07-27

Is there a completed human trial showing rapamycin extends lifespan?

No. As of 2026, there is no completed human trial with lifespan or all-cause mortality as an endpoint for sirolimus (rapamycin). This is the single most important fact in the entire longevity-rapamycin conversation, and it doesn't change no matter how compelling the mouse data looks. The reason is structural, not scientific reluctance. A human lifespan trial would need thousands of participants followed for decades, since healthy adults don't reliably die on a schedule researchers can study in a five-year grant cycle. The FDA has no approved indication for aging or lifespan extension at all; sirolimus is approved as an immunosuppressant for kidney transplant rejection (as Rapamune) and, in different formulations, for specific rare conditions like lymphangioleiomyomatosis and PEComa (Fyarro) and facial angiofibromas in tuberous sclerosis (Hyftor) ^[1]. Every use of rapamycin for aging, longevity, or general health optimization is off-label. What exists instead is a set of small, short-duration human trials looking at surrogate markers: immune response, frailty indices, skin aging, gene expression signatures tied to aging biology. These are useful and worth reading closely. They are not proof that rapamycin extends human life, and researchers running them say so directly.

What is the strongest evidence that rapamycin extends lifespan in animals?

The strongest evidence by far comes from mice, not humans, through the National Institute on Aging's Interventions Testing Program (ITP). This is a multi-site, replicated program specifically designed to avoid the single-lab, small-sample problems that plague most aging research. In the ITP's flagship study, rapamycin fed to genetically heterogeneous mice starting at 9 months of age extended median lifespan by about 9 to 14 percent in males and 13 to 21 percent in females, depending on dose, with effects growing larger at higher doses ^[2]. A later cohort found that even starting rapamycin at 20 months of age (roughly equivalent to a 60-year-old human) still extended lifespan, though by a smaller margin ^[3]. This matters because it suggests the drug doesn't need decades of early exposure to work, at least in mice. The ITP tests each compound across three sites (Jackson Laboratory, University of Michigan, University of Texas Health San Antonio) using genetically diverse mice, which makes its findings considerably more trustworthy than a single mouse study from one lab. Rapamycin remains, by NIA's own account, the most consistently reproduced lifespan-extending intervention the ITP has tested ^[2]. But mice are not small humans. Mouse trials run 2 to 4 years; human trials would need 20 to 40. Mice share the mTOR pathway with humans, but dosing, metabolism, and background disease risk differ enormously. Every serious researcher in this field treats the mouse data as a strong hypothesis generator, not a finished answer.

What human trials on rapamycin and aging actually exist?

A handful of small human trials have tested sirolimus or its analogs (rapalogs) against aging-adjacent outcomes, mostly immune function and frailty, not lifespan. The most cited is a 2014 Novartis-funded trial published in Science Translational Medicine, testing RAD001 (everolimus, a rapamycin analog) in adults over age 65. Low doses given for 6 weeks improved the response to influenza vaccination compared to placebo, and the study's authors concluded that "inhibition of mTOR enhanced the immune response to influenza vaccination in elderly subjects" ^[4]. This was framed as evidence that mTOR inhibition could improve an aging immune system, not as proof of lifespan extension. A follow-up 2018 study, again industry-funded, tested combinations of low-dose rapalogs in adults over 65 and found reduced rates of infection over the following year in some dose groups ^[5]. Again: infection rates, not mortality or biological age. On the frailty side, the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) is one of the only trials run through crowdfunded, participant-driven research rather than pharma sponsorship, testing low-dose intermittent rapamycin (5mg or 10mg weekly) in adults 50 to 85 over roughly 48 weeks, with frailty index and safety as primary outcomes. Interim and published results reported the drug was generally well tolerated at these doses, with mouth sores being the most common side effect, but the trial was not designed or powered to detect lifespan or major disease outcome differences ^[6]. Smaller studies have also looked at skin: a 2023 study applying topical rapamycin to skin over 8 months reported improvements in markers of skin aging and senescent cell burden in treated skin biopsies compared to untreated skin on the same person ^[7]. That's a real, measured finding, but it's about skin histology, not systemic aging or lifespan. | Study | Population | Duration | What it measured | Result |

Why hasn't anyone run a real human lifespan trial for rapamycin?

Cost and time, mostly, plus the fact that rapamycin is off-patent, which removes the usual pharma incentive to fund an expensive trial. A lifespan trial in humans needs a large cohort, likely thousands of people, followed for a couple of decades, at a cost that would run into the hundreds of millions of dollars. Generic sirolimus has been off-patent for years, so no drug company stands to recoup that investment through exclusive sales. This is the same economic problem that stalls research on metformin, aspirin repurposing, and most other generic longevity candidates: the science is interesting, but nobody with deep pockets has a return on it. What's happened instead is a shift toward composite biomarker trials, sometimes called "aging clock" studies, that try to measure biological age using DNA methylation clocks, inflammatory markers, or functional tests (grip strength, gait speed) as faster proxies for the real outcome. The TAME trial (Targeting Aging with Metformin) was designed with this kind of surrogate endpoint strategy in mind for metformin, and similar designs are being discussed for rapamycin, but as of 2026 no large-scale, prospective, randomized rapamycin trial with hard clinical endpoints (death, major disease incidence) has completed enrollment and reported results. Until that changes, everything sold as "the human evidence for rapamycin" is really a set of short, small, surrogate-marker studies plus a mountain of mouse data. Good hypothesis. Not yet a proven answer.

Are rapamycin and sirolimus the same drug?

Yes. Sirolimus is the generic drug name; rapamycin is the original chemical name derived from the compound isolated from soil bacteria on Rapa Nui (Easter Island), where it was first discovered in the 1970s ^[8]. They refer to the identical molecule. Brand name products vary by formulation and indication: Rapamune is the FDA-approved oral sirolimus for transplant rejection ^[1], Fyarro is an albumin-bound (nab-sirolimus) injectable form approved for malignant PEComa ^[1], and Hyftor is a topical sirolimus gel approved for facial angiofibromas in tuberous sclerosis complex ^[1]. Everolimus and temsirolimus are related but chemically distinct "rapalogs", not identical molecules, though they act on the same mTOR pathway and are sometimes used interchangeably in research discussions. When people in longevity communities talk about "rapamycin protocols," they almost always mean generic oral sirolimus, taken at low doses on an intermittent weekly schedule rather than the daily dosing used for transplant patients. That distinction matters for the safety conversation below.

What are the real risks of off-label, intermittent low-dose rapamycin?

The known risks come from decades of transplant medicine, where sirolimus is dosed daily and continuously, at levels generally higher than the once-weekly low-dose protocols popular in longevity circles. Whether the same risks apply at lower, intermittent doses is genuinely less established, which is itself part of the human evidence gap. Immunosuppression is the core mechanism-based risk. Sirolimus works by inhibiting mTOR, a pathway central to cell growth and immune activation, which is precisely why it prevents transplant rejection and precisely why it can blunt immune defenses against infection. The FDA label for Rapamune carries a boxed warning about increased susceptibility to infection and the risk of malignancy with immunosuppressive use . The 2018 Mannick trial actually found the opposite direction for infection risk at low intermittent doses in some groups ^[5], which is one reason researchers are interested in whether low-dose, pulsed regimens behave differently than continuous transplant dosing, but that hypothesis isn't confirmed at scale. Mouth ulcers (stomatitis) are the most consistently reported side effect across both transplant and off-label longevity dosing. The PEARL trial reported mouth sores as the most common adverse event among participants taking weekly rapamycin ^[6], and it's listed as a common adverse reaction in the Rapamune prescribing information . Metabolic effects are also real and worth taking seriously. Sirolimus is associated with elevated triglycerides and cholesterol, and in some patients, new-onset or worsened glucose intolerance, effects documented in the drug's prescribing information and in transplant literature . This runs counter to the popular longevity narrative that rapamycin is purely metabolically protective; the truth is more mixed and dose-dependent, and long-term metabolic effects of low-dose intermittent protocols in otherwise healthy adults haven't been studied over years. Other documented risks in the prescribing information include impaired wound healing, elevated blood pressure, and lipid abnormalities . Anyone considering off-label use should treat this as a real prescription drug with real monitoring needs (lipid panels, kidney function, blood counts), not a supplement.

Does low-dose intermittent dosing actually reduce these risks?

This is the honest crux of the human safety question, and the honest answer is: probably, to some degree, but it's not proven with long-term data. The theory behind weekly or twice-weekly low-dose protocols (as opposed to the daily dosing used in transplant medicine) is pharmacokinetic: intermittent dosing allows mTORC1 inhibition (the target believed responsible for benefits) while giving mTORC2 (linked more to some side effects, including metabolic ones) more time to recover between doses. This idea comes from mouse studies and some human PK modeling, and it's plausible, but it hasn't been confirmed with a large controlled human trial measuring hard outcomes over years. Short trials like PEARL (48 weeks) ^[6] and the Mannick studies (6 weeks to about a year) ^[4][5] give reassuring short-term safety signals at low doses: mouth sores are the main complaint, serious adverse events were uncommon in these small cohorts. But 48 weeks or a year is a thin basis for concluding a drug taken for a decade or more is safe. Nobody has that data yet, for the simple reason that the protocol itself is only about a decade old in casual off-label use. Anyone starting an off-label protocol should treat dosing itself as the primary safety lever, and this is exactly the kind of decision that should happen with bloodwork and a prescriber, not a forum thread. If you're weighing specific weekly doses, see Sirolimus Rx dosage and the Sirolimus Rx dosage calculator for how these protocols are typically structured, and Sirolimus Rx cycle length for how on/off scheduling is usually approached.

What do researchers say when asked directly if rapamycin extends human life?

The most consistent answer from researchers actually running these trials is careful and hedged, not promotional. The 2014 Mannick trial's own conclusion was scoped narrowly to immune function: the drug "enhanced the immune response to influenza vaccination in elderly subjects," a finding the authors themselves did not extend into lifespan claims ^[4]. The NIA's own materials on the Interventions Testing Program describe rapamycin's lifespan effect in mice while consistently framing the program's purpose as identifying candidates worth further study, not declaring a human therapy validated ^[2]. That's the tone throughout legitimate aging research: rapamycin is the most reproducible lifespan-extending compound tested in mice to date, which is exactly why it's the top candidate for eventual human trials, and exactly why it isn't yet a proven human intervention. The gap between "most promising candidate" and "proven to work in humans" is the entire story here, and it's worth restating because marketing copy around rapamycin tends to blur it. Strong animal case, real but narrow human data, no completed lifespan trial. All three of those things are true at once.

How do you weigh the evidence if you're considering rapamycin anyway?

If you're a researcher or a well-informed patient weighing this off-label, the honest framing is: you'd be acting on a strong mechanistic and animal case, a handful of short reassuring human safety/surrogate-marker studies, and zero human lifespan data. That's a real decision people make, but it should be made with eyes open and with a prescriber managing labs and dose. Practical due diligence looks like: baseline and periodic lipid panel, fasting glucose or HbA1c, kidney function, and blood counts, given the documented metabolic and immune effects in the prescribing information . It also means understanding the injection or oral dosing logistics if using compounded formulations; guidance on reconstitution (how to reconstitute Sirolimus Rx), injection technique (Sirolimus Rx how to inject), and site rotation (Sirolimus Rx injection sites) matters for anyone using injectable formulations, though oral sirolimus remains the more common route in longevity protocols. Sirolimus Rx's provider-reviewed process exists for exactly this reason: off-label rapamycin use should run through a prescriber who orders labs, adjusts dose based on your bloodwork, and watches for the documented risks (infection susceptibility, lipid changes, mouth ulcers) rather than a self-directed purchase with no monitoring. When a prescription is appropriate, fulfillment through a licensed pharmacy partner keeps the chain of accountability intact, which matters more for a drug with a boxed warning than for almost anything else discussed in longevity circles.

What would it take to get a real human lifespan trial?

Money, time, and a funding model that doesn't depend on patent exclusivity. Realistically, a trial capable of answering the mortality question would need a multi-year to multi-decade follow-up window, thousands of participants, and funding in the hundreds of millions of dollars, similar in scale to major cardiovascular outcome trials. The more likely near-term path is what's already happening: smaller trials using biomarker composites and functional endpoints (grip strength, gait speed, inflammatory markers, epigenetic clocks) as faster surrogates, following the design logic used for the metformin-focused TAME trial concept. If a surrogate-marker trial shows a strong, consistent signal across multiple biomarkers, that could build the case for a larger outcomes trial, public or philanthropically funded, since a generic drug won't attract standard pharma R&D dollars. Until something like that reports results, the state of the science stays exactly where it is now: extremely promising in mice, encouraging but narrow in short human studies, and completely unproven for the one question everyone actually wants answered.

Frequently asked questions

Has rapamycin been proven to extend human lifespan?

No. No completed human trial has tested sirolimus (rapamycin) against mortality or lifespan as an endpoint. The lifespan-extension evidence comes from mouse studies, particularly the NIA's Interventions Testing Program, which found consistent lifespan extension across multiple cohorts ^[2][3]. Human data is limited to short trials on immune function, frailty, and skin aging markers.

What's the difference between rapamycin and sirolimus?

Nothing chemically; they're the same molecule. Rapamycin is the original name from the compound isolated on Rapa Nui in the 1970s ^[8], while sirolimus is the generic drug name used in FDA labeling. Brand products like Rapamune (oral), Fyarro (nab-sirolimus injectable), and Hyftor (topical) are FDA-approved formulations of sirolimus for specific non-aging indications ^[1].

Is rapamycin FDA-approved for anti-aging use?

No. Sirolimus is FDA-approved only for kidney transplant rejection (Rapamune), malignant PEComa (Fyarro), and facial angiofibromas in tuberous sclerosis (Hyftor) ^[1]. Any use for aging, longevity, or general health optimization is off-label, meaning a prescriber is using an approved drug for an unapproved purpose based on their clinical judgment and the available evidence, not an FDA-sanctioned use.

What did the PEARL trial find about rapamycin in humans?

PEARL tested low-dose intermittent rapamycin (5mg or 10mg weekly) in adults aged 50 to 85 over about 48 weeks, measuring frailty index and safety. It found the drug generally well tolerated, with mouth sores as the most common side effect ^[6]. It was not designed to detect lifespan or major disease outcome differences, only short-term tolerability and functional markers.

Does rapamycin improve immune function in older adults?

One trial found low-dose everolimus (a rapamycin analog) improved influenza vaccine response in adults over 65 after 6 weeks of treatment, with study authors concluding it "enhanced the immune response to influenza vaccination in elderly subjects" ^[4]. A follow-up study found reduced infection rates at some doses over about a year ^[5]. Both are short-term, surrogate-marker findings, not proof of overall immune benefit long-term.

What are the main risks of taking rapamycin off-label?

The documented risks include immunosuppression and increased infection susceptibility, mouth ulcers (the most commonly reported side effect in human trials), elevated cholesterol and triglycerides, glucose intolerance, and impaired wound healing, all listed in the Rapamune prescribing information ^[9]. Long-term data on low-dose intermittent protocols specifically is limited, since most safety data comes from daily transplant dosing.

Why hasn't a real human lifespan trial for rapamycin been done yet?

Cost and time are the main barriers. A trial capable of detecting a lifespan effect would need thousands of participants followed for one to several decades, likely costing hundreds of millions of dollars. Because generic sirolimus is off-patent, no pharmaceutical company has a commercial incentive to fund that scale of trial, unlike patented drugs in development.

How much did rapamycin extend lifespan in mouse studies?

In the NIA's Interventions Testing Program, rapamycin extended median lifespan by roughly 9 to 14 percent in male mice and 13 to 21 percent in female mice, depending on dose, when started at 9 months of age ^[2]. A later cohort found lifespan extension even when treatment started at 20 months of age, though the effect was smaller ^[3].

Does intermittent low-dose rapamycin have fewer side effects than daily transplant dosing?

It's plausible based on pharmacokinetic theory (sparing mTORC2 between doses) and reassuring short-term trial results, but this hasn't been confirmed in a large, long-duration human trial. Short trials of 6 weeks to about a year show mouth sores as the main complaint at low doses ^[4][5][6], but multi-year safety data for intermittent protocols doesn't yet exist.

Can rapamycin cause weight gain or metabolic problems?

Sirolimus is associated with elevated triglycerides, elevated cholesterol, and in some patients, new or worsened glucose intolerance, documented in its FDA prescribing information ^[9]. This runs against the popular idea that rapamycin is purely metabolically protective; the real picture is dose-dependent and more mixed than longevity marketing often suggests.

What is the NIA Interventions Testing Program and why does it matter for rapamycin?

The Interventions Testing Program (ITP) is a National Institute on Aging initiative that tests candidate longevity compounds across three research sites simultaneously in genetically diverse mice, reducing the single-lab bias common in aging research. Rapamycin is the ITP's most consistently reproduced lifespan-extending compound to date ^[2], making it the top candidate for eventual human study, though no human trial has confirmed the effect.

Is topical rapamycin proven to reduce skin aging in humans?

One small study found that applying topical rapamycin to skin over 8 months reduced markers of cellular senescence in treated skin biopsies compared to untreated skin on the same person ^[7]. That's a real, localized finding about skin tissue markers, not evidence of systemic anti-aging effects or lifespan extension.

Sources

1. FDA, Drugs@FDA (Rapamune, Fyarro, Hyftor approval records): Sirolimus is FDA-approved as Rapamune for transplant rejection, Fyarro for malignant PEComa, and Hyftor for facial angiofibromas in tuberous sclerosis
2. National Institute on Aging, Interventions Testing Program: Rapamycin extended median lifespan in genetically heterogeneous mice across multiple ITP cohorts and is the program's most consistently reproduced lifespan-extending compound
3. Harrison DE et al., 'Rapamycin fed late in life extends lifespan in genetically heterogeneous mice', Nature 2009: Rapamycin extended lifespan in mice even when treatment began at 20 months of age
4. Mannick JB et al., 'mTOR inhibition improves immune function in the elderly', Science Translational Medicine 2014: Low-dose RAD001 (everolimus) improved influenza vaccine antibody response in adults over 65 after 6 weeks
5. Mannick JB et al., 'TORC1 inhibition enhances immune function and reduces infections in the elderly', Science Translational Medicine 2018: Low-dose rapalog combinations reduced infection rates in adults over 65 over about a year in some dose groups
6. PEARL Trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published results: Weekly low-dose rapamycin (5mg or 10mg) was generally well tolerated in adults 50-85 over 48 weeks, with mouth sores as the most common adverse event
7. Chung CL et al., topical rapamycin skin senescence study: Topical rapamycin applied over 8 months reduced markers of cellular senescence in treated skin biopsies
8. NIH National Cancer Institute, sirolimus drug information: Rapamycin is the original name of the compound isolated from bacteria found on Rapa Nui (Easter Island)